Education
About Us
Working with TipRanks
Follow Us
Dr. Lal PathLabs Limited (IN:LALPATHLAB)
:LALPATHLAB
LALPATHLAB Stock Chart & Stats
₹1472.95
-₹106.10(-3.42%)
At close: 4:00 PM EST
₹1472.95
-₹106.10(-3.42%)
Day’s Range― - ―
52-Week Range₹1,187.50 - ₹1,771.30
Previous CloseN/A
Volume152.98K
Average Volume (3M)3.61K
Market Cap
₹227.86B
Enterprise Value₹221.47B
Total Cash (Recent Filing)₹11.64B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)68.4
Beta0.71
Next Earnings
May 14, 2026EPS Estimate
7.4Next Dividend Ex-DateN/A
Dividend Yield0.89%
Share Statistics
EPS (TTM)6.70
Shares Outstanding167,555,020
10 Day Avg. Volume2,182
30 Day Avg. Volume3,614
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)9.21
Price to Sales (P/S)8.13
P/FCF Ratio38.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,577.00Price Target Upside7.06% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)30.53
Revenue Forecast (FY)₹27.36B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthThe company has delivered sustained top-line expansion (RevenueGrowth ~10.8%) and a documented rise in total revenue year-over-year. Durable revenue growth supports capacity utilization, network investments and long-term market share gains in diagnostics across its patient and B2B channels.
High And Sustainable MarginsRobust gross and net margins indicate strong pricing power, efficient lab operations and favorable test mix. Sustained 60%+ gross margins and near-20% net margins underpin cash generation and reinvestment capacity, supporting competitive positioning in diagnostics over the medium term.
Strong Cash Generation And FCF GrowthOperating cash flows align with net income and free cash flow has expanded, showing the business converts earnings into usable liquidity. Reliable FCF strengthens balance sheet flexibility for capex, network expansion or opportunistic M&A without heavy reliance on external funding.
Bears Say
Moderate Return On EquityDespite strong revenue and margin profiles, ROE is flagged as below potential, suggesting the company may not be fully leveraging its equity base to generate shareholder returns. Over the medium term this can limit investor return if not addressed via operational or capital allocation changes.
Fluctuations In Investing/financing Cash FlowsWhile operating cash flow is healthy, variability in investing and financing flows indicates episodic capital spending or financing moves. Such fluctuations can complicate longer-term planning, signal uneven capital allocation, and introduce execution risk for expansion or M&A strategies.
Revenue Sensitive To Volumes And Test MixRevenue depends materially on sample volumes, test mix and network density; adverse shifts (fewer routine tests or unfavorable mix toward lower‑margin services) would pressure top-line and margins. Structural demand changes or slower volume growth could constrain medium-term revenue momentum.
Dr. Lal PathLabs Limited News
LALPATHLAB FAQ
What was Dr. Lal PathLabs Limited’s price range in the past 12 months?
Dr. Lal PathLabs Limited lowest stock price was ₹1187.50 and its highest was ₹1771.30 in the past 12 months.
What is Dr. Lal PathLabs Limited’s market cap?
Dr. Lal PathLabs Limited’s market cap is ₹227.86B.
When is Dr. Lal PathLabs Limited’s upcoming earnings report date?
Dr. Lal PathLabs Limited’s upcoming earnings report date is May 14, 2026 which is in 66 days.
How were Dr. Lal PathLabs Limited’s earnings last quarter?
Dr. Lal PathLabs Limited released its earnings results on Jan 30, 2026. The company reported ₹6.7 earnings per share for the quarter, missing the consensus estimate of ₹7.625 by -₹0.925.
Is Dr. Lal PathLabs Limited overvalued?
According to Wall Street analysts Dr. Lal PathLabs Limited’s price is currently Undervalued.
Does Dr. Lal PathLabs Limited pay dividends?
Dr. Lal PathLabs Limited pays a Quarterly dividend of ₹7 which represents an annual dividend yield of 0.89%. See more information on Dr. Lal PathLabs Limited dividends here
What is Dr. Lal PathLabs Limited’s EPS estimate?
Dr. Lal PathLabs Limited’s EPS estimate is 7.4.
How many shares outstanding does Dr. Lal PathLabs Limited have?
Dr. Lal PathLabs Limited has 167,555,020 shares outstanding.
What happened to Dr. Lal PathLabs Limited’s price movement after its last earnings report?
Dr. Lal PathLabs Limited reported an EPS of ₹6.7 in its last earnings report, missing expectations of ₹7.625. Following the earnings report the stock price went up 0.946%.
Which hedge fund is a major shareholder of Dr. Lal PathLabs Limited?
Currently, no hedge funds are holding shares in IN:LALPATHLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company also offers lab staff training; technical; and lab management services. As of March 31, 2022, the company had 277 clinical laboratories, including National Reference Lab at Delhi and Regional Reference Lab at Kolkata; and 4,731 patient service centers and 10,599 pick-up points. Dr. Lal PathLabs Limited was founded in 1949 and is based in Gurugram, India.
LALPATHLAB Stock 12 Month Forecast
Average Price Target
₹1,577.00
▲(7.06% Upside)
Technical Analysis
Jupiter Life Line Hospitals Ltd.
―
Krsnaa Diagnostics Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―